The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene.
Open accessAbstract
The insulin-like growth factor I receptor (IGF-I-R) plays a critical role in transformation events. It is highly overexpressed in most malignant tissues where it functions as an anti-apoptotic agent by enhancing cell survival. Tumor suppressor p53 is a nuclear transcription factor that blocks cell cycle progression and induces apoptosis. p53 is the most frequently mutated gene in human cancer. Cotransfection of Saos-2 (os-teosarcoma-derived cells) and RD (rhabdomyosarcoma-derived cells) cells with IGF-I-R promoter constructs driving luciferase reporter genes and with wild-type p53 expression vectors suppressed promoter activity in a dose-dependent manner. This effect of p53 is mediated at the level of transcription and it involves interaction with TBP, the TATA box-binding component of TFIID. On the other hand, three tumor-derived mutant forms of p53 (mut 143, mut 248, and mut 273) stimulated the activity of the IGF-I-R promoter and increased the levels of IGF-I-R/luciferase fusion mRNA. These results suggest that wild-type p53 has the potential to suppress the IGF-I-R promoter in the postmitotic, fully differentiated cell, thus resulting in low levels of receptor gene expression in adult tissues. Mutant versions of p53 protein, usually associated with malignant states, can derepress the IGF-I-R promoter, with ensuing mitogenic activation by locally produced or circulating IGFs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease
Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., & Rutter, W. J. (1979) · Biochemistry · doi:10.1021/bi00591a005 · Cited by 21,725
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
High-efficiency transformation of mammalian cells by plasmid DNA.
Chen, C., & Okayama, H. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.8.2745 · Cited by 5,373
Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions*
JONES, J. I., & CLEMMONS, D. R. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-3 · Cited by 4,710
Liu, J.-P., Baker, J., Perkins, A. S., Robertson, E. J., & Efstratiadis, A. (1993) · Cell · doi:10.1016/s0092-8674(05)80084-4 · Cited by 2,855
Role of insulin-like growth factors in embryonic and postnatal growth
Baker, J., Liu, J.-P., Robertson, E. J., & Efstratiadis, A. (1993) · Cell · doi:10.1016/s0092-8674(05)80085-6 · Cited by 2,463
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53
Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., & Vogelstein, B. (1990) · Science · doi:10.1126/science.2144057 · Cited by 1,754
DAUGHADAY, W. H., & ROTWEIN, P. (1989) · Endocrine Reviews · doi:10.1210/edrv-10-1-68 · Cited by 1,725
The “initiator” as a transcription control element
Smale, S. T., & Baltimore, D. (1989) · Cell · doi:10.1016/0092-8674(89)90176-1 · Cited by 1,535
Molecular and Cellular Aspects of the Insulin-Like Growth Factor I Receptor
LEROITH, D., WERNER, H., BEITNER-JOHNSON, D., & ROBERTS, A. T. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-2-143 · Cited by 1,423
Self-citationClinical Implications of the p53 Tumor-Suppressor Gene
Harris, C. C., & Hollstein, M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310283291807 · Cited by 1,330
DNA-dependent transcription of adenovirus genes in a soluble whole-cell extract.
Manley, J. L., Fire, A., Cano, A., Sharp, P. A., & Gefter, M. L. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.7.3855 · Cited by 1,211
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Induction of the growth inhibitor IGF-binding protein 3 by p53
Buckbinder, L., Talbott, R., Velasco-Miguel, S., Takenaka, I., Faha, B., Seizinger, B. R., & Kley, N. (1995) · Nature · doi:10.1038/377646a0 · Cited by 869
Modulation of Activity of the Promoter of the Human MDR 1 Gene by Ras and p53
Chin, K.-V., Ueda, K., Pastan, I., & Gottesman, M. M. (1992) · Science · doi:10.1126/science.1346476 · Cited by 726
Absence of HeLa Cell Contamination in 169 Cell Lines Derived From Human Tumors2
Fogh, J., Wright, W. C., & Loveless, J. D. (1977) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/58.2.209 · Cited by 663
Wild-type p53 activates transcription in vitro
Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., & Prives, C. (1992) · Nature · doi:10.1038/358083a0 · Cited by 579
Sell, C., Rubini, M., Rubin, R., Liu, J. P., Efstratiadis, A., & Baserga, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.11217 · Cited by 553
The insulin-like growth factor I receptor: a key to tumor growth?
Baserga, R. (1995) · PubMed · Cited by 552
Sell, C., Dumenil, G., Deveaud, C., Miura, M., Coppola, D., DeAngelis, T., Rubin, R., Efstratiadis, A., & Baserga, R. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.6.3604 · Cited by 538
Wild-type p53 binds to the TATA-binding protein and represses transcription.
Seto, E., Usheva, A., Zambetti, G. P., Momand, J., Horikoshi, N., Weinmann, R., Levine, A. J., & Shenk, T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12028 · Cited by 504
Sequence-specific transcriptional activation is essential for growth suppression by p53.
Pietenpol, J. A., Tokino, T., Thiagalingam, S., el-Deiry, W. S., Kinzler, K. W., & Vogelstein, B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.1998 · Cited by 406
The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo.
Resnicoff, M., Abraham, D., Yutanawiboonchai, W., Rotman, H. L., Kajstura, J., Rubin, R., Zoltick, P. W., & Baserga, R. (1995) · PubMed · Cited by 385
Developmental regulation of the rat insulin-like growth factor I receptor gene.
Werner, H., Woloschak, M., Adamo, M., Shen-Orr, Z., Roberts, C. T., & LeRoith, D. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7451 · Cited by 331
Self-citationSpecific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53
Mack, D. H., Vartikar, J., Pipas, J. M., & Laimins, L. A. (1993) · Nature · doi:10.1038/363281a0 · Cited by 322
The Role of the Insulin-like Growth Factor System in Human Cancer
(1996) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60354-1 · Cited by 293
Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis.
Sell, C., Baserga, R., & Rubin, R. (1995) · PubMed · Cited by 287
Oncogenes and the strategy of growth factors
Baserga, R. (1994) · Cell · doi:10.1016/0092-8674(94)90023-x · Cited by 230
EGR3, a novel member of the Egr family of genes encoding immediate-early transcription factors.
Patwardhan, S., Gashler, A., Mg, S., Chang, L. C., Joseph, L. J., Shows, T. B., Beau, M. M. L., & Sukhatme, V. P. (1991) · PubMed · Cited by 220
p53: the ultimate tumor suppressor gene?
Oren, M. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.13.1397838 · Cited by 206
Truant, R., Xiao, H., Ingles, C. J., & Greenblatt, J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53769-8 · Cited by 203
Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma.
Felix, C. A., Kappel, C. C., Mitsudomi, T., Nau, M. M., Tsokos, M., Crouch, G. D., Nisen, P. D., Winick, N. J., & Helman, L. J. (1992) · PubMed · Cited by 180
Ueba, T., Nosaka, T., Takahashi, J. A., Shibata, F., Florkiewicz, R. Z., Vogelstein, B., Oda, Y., Kikuchi, H., & Hatanaka, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.9009 · Cited by 142
Insulin-like Growth Factors: Molecular and Cellular Aspects
LeRoith, D. (1991) · Medical Entomology and Zoology · Cited by 141
Self-citationAnalysis of human p53 proteins and mRNA levels in normal and transformed cells
Matlashewski, G., Banks, L., Pim, D., & Crawford, L. (1986) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1986.tb09449.x · Cited by 139
Zhang, L., Kashanchi, F., Zhan, Q., Zhan, S., Brady, J. N., Fornace, A. J., Seth, P. K., & Helman, L. J. (1996) · PubMed · Cited by 121
Werner, H., Shen‐Orr, Z., Rauscher, F. J., Morris, J. F., Roberts, C. T., & LeRoith, D. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.7.3516 · Cited by 111
Self-citationZenzie-Gregory, B., Khachi, A., Garraway, I. P., & Smale, S. T. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.7.3841 · Cited by 109
Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro.
Bohan, C. A., Kashanchi, F., Ensoli, B., Buonaguro, L., Boris‐Lawrie, K., & Brady, J. N. (1992) · Europe PMC (PubMed Central) · Cited by 90
Werner, H., STANNARD, B. S., Bach, M. A., LeRoith, D., & Roberts, C. T. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)91996-6 · Cited by 84
Self-citationMolecular and Cellular Aspects of Insulin-like Growth Factor Action
Werner, H., Adamo, M. L., Roberts, C. T., & LeRoith, D. (1994) · Vitamins and hormones · doi:10.1016/s0083-6729(08)60495-1 · Cited by 83
Self-citation
Cited by
Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression
Yu, H. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.18.1472 · Cited by 1,424
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
The insulin-like growth factor system and cancer
LeRoith, D., & Roberts, C. T. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00159-9 · Cited by 1,124
Self-citationThe Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights
Samani, A. A., Yakar, S., LeRoith, D., & Brodt, P. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0001 · Cited by 1,005
Self-citation
Metadata
- Authors
- Werner, H., Karnieli, E., Rauscher, F. J., & LeRoith, D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1996-08-06
- Volume
- 93
- Issue
- 16
- Pages
- 8318-8323
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2085020132
- Cited by
- 370
- References
- 43
- FWCI
- 8.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.